Predictors of treatment‐response to caffeine combination products, acetaminophen, acetylsalicylic acid (aspirin), and nonsteroidal anti‐inflammatory drugs in acute treatment of episodic migraine
Headache: The Journal of Head and Face Pain · 2023-03 · 63 (3) · 342-352
DOI: 10.1111/head.14459 ↗Kurz gefasst
Fachartikel in der Zeitschrift Headache: The Journal of Head and Face Pain, online erschienen am 07.02.2023. Verfasst von Ali Ezzati und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA. Hauptthemen laut MEDLINE: Acetaminophen, Migraine Disorders. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: GlaxoSmithKline Plc (GSK), GlaxoSmithKline.
Abstract (Originalsprache)
Objective
To identify predictors of acute treatment optimization for migraine with “over‐the‐counter” (OTC) or prescription nonsteroidal anti‐inflammatory drugs (NSAIDs) as well as other widely used OTCs including acetaminophen, caffeine combination products (CCP), and acetylsalicylic acid (ASA, aspirin) among people with episodic migraine and to develop models that predict treatment response to each class of OTCs.
Background
Efficacy of acute OTC medications for migraine varies greatly. Identifying predictors of treatment response to particular classes of medication is a step toward evidence‐based personalized therapy.
Methods
For this prediction model development study, we used data from 2224 participants from the American Migraine Prevalence and Prevention (AMPP) study who were aged ≥18 years, met criteria for migraine, had
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
- Mist Research, Wilmington, North Carolina, USA.
- Vedanta Research, Chapel Hill, North Carolina, USA.
ORCID-Profile: Ali Ezzati
Förderung
- GlaxoSmithKline Plc (GSK)
- GlaxoSmithKline
Zitieren
APA
Ezzati, A., Fanning, K. M., Reed, M. L., & Lipton, R. B. (2023). Predictors of treatment‐response to caffeine combination products, acetaminophen, acetylsalicylic acid (aspirin), and nonsteroidal anti‐inflammatory drugs in acute treatment of episodic migraine. Headache: The Journal of Head and Face Pain, 63(3), 342-352. https://doi.org/10.1111/head.14459
Vancouver
Ezzati A, Fanning KM, Reed ML, Lipton RB. Predictors of treatment‐response to caffeine combination products, acetaminophen, acetylsalicylic acid (aspirin), and nonsteroidal anti‐inflammatory drugs in acute treatment of episodic migraine. Headache: The Journal of Head and Face Pain. 2023;63(3):342-352. doi:10.1111/head.14459
BibTeX
@article{Ezzati2023,
author = {Ezzati, Ali and Fanning, Kristina M and Reed, Michael L and Lipton, Richard B},
title = {Predictors of treatment‐response to caffeine combination products, acetaminophen, acetylsalicylic acid (aspirin), and nonsteroidal anti‐inflammatory drugs in acute treatment of episodic migraine},
journal = {Headache: The Journal of Head and Face Pain},
year = {2023},
volume = {63},
number = {3},
pages = {342--352},
doi = {10.1111/head.14459}
}
EUVIMED